TSO₃ appoints new V P Sales for US market

March 22, 2004

Québec City, March 22, 2004 – TSO3 Inc. (“TSO3”) has appointed Ann Hewitt, a former STERIS Corporation sales and marketing executive, as Vice President, Sales – US Market and as a replacement for James M. Mazzarella. She will be responsible for the market launch of the 125L Ozone Sterilizer in the United States and will be supporting the efforts of TSO3’s distributor, Skytron, along with her team. 

 “Ann Hewitt’s career is a twenty year cumulation of outstanding accomplishments in employee hiring, training, and marketing, as well as customer acceptance of new technologies in the healthcare industry..  She is well respected and trusted, and she will be instrumental in maximizing market adoption of our ozone technology in the United States,” said Jocelyn Vézina, CEO at TSO3.

Ms. Hewitt has an extensive background in healthcare sales, marketing, education and management, with a strong focus on innovative technology and start-up ventures. As part of the original STERIS sales team, she was instrumental in the successful and rapid growth of that company while she worked there for 8 years as the company went from $8 Million to a $800 Million in revenues. STERIS Corporation is currently the biggest company in sterilization in North America. She holds a Bachelor of Science in Nursing from the University of Virginia, and an MBA from the Kellogg Graduate School of Management at Northwestern University.

“Ann Hewitt replaces James M. Mazzarella who has resigned to pursue other opportunities.  Before leaving, he noted, ‘The TSO3 technology certainly has promise.  The market is definitely looking for alternatives to current methods of sterilization.’  We are grateful for the contributions Mr. Mazzarella has made to the company in preparing the launch of  the 125L in the United States,” added Jocelyn Vézina.

About TSO3

TSO3 Inc. is located in Québec City (Québec, Canada) and was founded in 1998. TSO3 currently has 43 employees, 16 of whom work exclusively in the Research and Development Department. The company’s mission is to develop and market innovative and comprehensive sterilization solutions.

TSO3 has perfected a novel sterilization process using ozone as a sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize the new generation of surgical and diagnostic instruments made of non-heat-resistant materials such as polymers and plastics. The ozone sterilization process is a safe, efficient, fast and cost-effective response to evolving sterilization needs.

The 125L Ozone Sterilizer was licensed by Health Canada in May 2002 and TSO3 was granted U.S. Food and Drug Administration (FDA) approval September 3, 2003.

The Company’s R&D team has also undertaken the development of a smaller, point-of-use ozone sterilization device for operating rooms and private clinics, and is planning the development of an industrial-sized device for manufacturers of medical instruments, among others.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3 are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -